Skip to Content

Real-world studies studies highlight NSCLC data gaps and survival differences from randomized controlled trials

In this MEDtalk, Birgitte Bjørnhart of the Department of Oncology at Odense University Hospital presents the outcomes of two national studies involving the treatment of non-small cell lung cancer (NSCLC) patients with immune-checkpoint inhibitors. During her presentation, she examines the differences between real-world studies and randomized controlled trials.

Birgitte Bjørnhart

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top